Editing the Human Genome
By BBC Newshour Extra,
BBC Newshour Extra
| 11. 28. 2015
Remarkable new techniques for ‘editing’ DNA – chemically cutting and splicing sections of genetic code – are revolutionising research in laboratories around the world. The potential for eradicating hereditary diseases is enormous. But are the benefits outweighed by the risks involved? And should these techniques ever be used on humans? On Newshour Extra this week, Owen Bennett Jones and his panel of expert guests discuss the scientific and ethical consequences of this latest research, and ask whether mankind should be tinkering with our genetic inheritance.
Contributors: Prof Robin Lovell-Badge - Head of Stem Cell Biology and Developmental Genetics at the Francis Crick Institute; Michael Le Page -New Scientist magazine; Dr Annelien Bredenoord - Associate Professor of Biomedical Ethics at the University Medical Centre in Utrecht; Marcy Darnovsky - Executive Director of the Center for Genetics and Society, Berkeley, California; James Rushbrooke - playwrite; Edward Perello - co-founder of Desktop Genetics
Related Articles
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
